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Summary 
Autoantibodies occur in low frequencies among patients with myositis characterizing only dis- 
tinct subsets of this disease. Most of these known antibodies are directed to enzymatically active 
complexes. The 20S proteasome r presents an essential cytoplasmatic protein complex for in- 
tracellular nonlysosomal protein degradation, and is involved in major histocompatibility com- 
plex class I restricted antigen processing. In this study we investigated whether the 20S protea- 
some complex is an antibody target in myositis and in other autoimmune diseases. 34 sera of 
poly/derrnatomyositis patients were assayed for antiproteasomal antibodies using enzyme- 
linked immunosorbent assay, immunoblot, and two-dimensional non-equilibrium pH gradient 
electrophoresis (NEPHGE). Sera was from patients with systemic lupus erythematosus (SLE), 
mixed connective tissue disease, and rheumatoid arthritis; healthy volunteers served as controls. 
In 62% (21/34) of the cases sera from patients with myositis and in 58% (30/52) of the cases 
sera from patients with SLE reacted with the 20S proteasome. These frequencies exceeded 
those of sera from patients with mixed connective tissue disease, rheumatoid arthritis, and 
healthy controls. The c~-type subunit C9 of the 20S proteasome was determined to be the pre- 
dominant target of the autoimmune s ra in myositis and SLE. Lacking other frequent autoanti- 
bodies in myositis, the antiproteasome antibodies are the most common humoral immune re- 
sponse so far detected in this disease ntity. 
W ithin eukaryotic ells the 20S proteasome (multicat- alytic proteinase complex) represents the key en- 
zyme complex responsible for intracellular nonlysosomal 
protein degradation, and is the proteolytic ore of an even 
larger 26S protease complex which is involved in the ATP/ 
ubiquitin-dependent protein degradation (1). Proteasomes 
are involved in the degradation or processing of transcrip- 
tions factors uch as nuclear factor (NF)KB, in cyclin degra- 
dation, cell cycle control, and apoptosis (1-4). Further- 
more, the synthesis of the ~3-type subunits LMP2, LMP7, 
and MECL1, as well as the PA28 regulator, are inducible 
by IFN-% and the role of the 20S proteasome in the pro- 
cessing of antigens presented by MHC class I molecules is 
now well established. Analysis of the structure and subunit 
sequences revealed that the proteasome is highly conserved 
among species as far apart in evolution as bacteria nd man 
(5-8). In eukaryotes the cylindrical structure of protea- 
somes is arranged in four staggered tings composed of 28 
subunits whereby each ring contains even different pro- 
teins. The or subunits are located in the outer rings 
and are the contact sites for regulatory complexes uch as 
the 11S regulator PA28 and the 19S complexes. Four of 
the or-type subunits carry putative nuclear location signals 
and several are substrates for protein kinases (9). The ~3-type 
subunits forming the two adjacent inner rings carry the 
proteolytically active sites. As deduced from the crystal 
structure of the thermoplasma proteasome and mutagenesis 
only three out of the seven mammalian [3-type subunits 
within one ring form active sites with the NH2-terminal 
threonine being the catalytically active residue (10, 11). 
Autoantibodies play an important diagnostic role in 
many autoimmune diseases. Thus, anti-tRNA synthetase 
autoantibodies occurring in myositis patients characterize 
clinically different patient subsets (12). The cytoplasmatic 
aminoacyl-tRNA synthetases catalyze the binding of amino 
acids to their cognate tRNA, and five of them have been 
determined to be the antigens of specific autoantibody 
subtypes (13). Nevertheless, among myositis patients these 
specific antibodies are present at relatively low frequency 
(5-20~ (13). 
The objective of the present study was to determine 
whether specific subunits of the abundant proteasome 
complex represent disease-specific autoantigens. Therefore, 
sera of different ypes of chronic inflammatory autoim- 
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mune diseases (polymyositis [PM] i, dermatomyosit is [DM], 
SLE, mixed connect ive tissue disease [MCTD]) ,  rheuma-  
toid arthritis (RA), and sera from healthy controls were tested 
in ELISA, immunoblot ,  and two-dimensional  NEPHGE.  
The experiments how for the first t ime that sera from pa- 
tients with PM and DM as well  as SLE patients contain an- 
t iproteasome antibodies at high frequencies. Furthermore,  
we demonstrate that the proteasomal R-type subunit C9 
represents a major immune target of  reactive sera. 
Materials and Methods 
Patient Sera. Sera of the following individuals were investi- 
gated: 8 patients with DM and 26 patients with PM classified ac- 
cording to Bohan and Peter (14, 15), 52 patients with SLE fulfill- 
ing the 1982 revised ACR. criteria 06), 10 patients with MCTD 
diagnosed according to Sharp et al. (17), 20 patients with tkA 
(18), and 112 healthy controls. Materials were obtained at the 
university hospital of the Charit8 Berlin. 
Pur!ficatio~t of20S Proteasome. 20S proteasomes were isolated 
from human erythrocytes following standard procedures, and 
analysis ofproteasome subunits by two-dimensional electrophoresis 
(NEPHGE/SDS-PAGE) was carried out as described (19, 20). 
Monoclonal Antl~vroteasorne Antibodies. Mice were injected in- 
traperitoneally with ~25 to 100 Fig proteasome protein in about 
100-200 ~zl PBS as a water in oil mixture in the same amount  of 
CFA. Booster injections were given after a resting period of 2-3 
too. Antibody activity was determined in the serum of immu- 
nized mice in general 7 d after immunization. Spleen cells were 
taken 4 d after the last booster injection and fused with X63 
Ag8.653 nweloma cells using polyethylene glycol. A small por- 
tion of the spleen cells was taken into culture for 7-10 d and anti- 
body activity was measured in solid-phase binding assays after ad- 
sorbing the first reactant to polyvinyl chloride plates according to 
our general methods (21,22). The incubation sequences were as 
follows: proteasome, antibody-containing solution, biotin-labeled 
sheep anti-mouse Is, streptavidin-galactosidase complex. The 
fluorescence of the substrate 4-methylumbelliferyl galactoside was 
measured at 355 nm. 
lmmunoblotting. For immunoblotting, purified proteins were 
separated by 15% SDS-PAGE and were transferred onto nitrocel- 
lulose membranes. The remaining binding sites were blocked for 
2 h with PBS, pH 7.4, containing 5% skim milk. Subsequently, 
the patient's sera diluted l:100 were added. The antibodies 
bound to the proteasome were detected by rabbit anti-human 
IgG antibodies coupled with horseradish peroxidase diluted 1: 
10,000 in PBS/1% Tween 20/1% skim milk. Antibodies bound 
were visualized using x-ray films exposed to enhanced chemilu- 
minescence-treated blots (Boehringer Mannheim GmbH, Man- 
nheim, Germany). 
ELISA. Multititer plates were coated overnight with l btg/ml 
of the purified proteasome in carbonate buffer, pH 9.6. Remain- 
ing binding sites were blocked with 0.5% skim milk and 0.05% 
Tween 20 in PBS, pH 7.4. Human sera were diluted 1:100 and 
applied to each well for 2 h at room temperature. Anti-human 
IgG peroxidase-labeled antibody (I ms/liter) was used as the sec- 
ond reagent. Bound antibodies were detected enzymatically with 
* AbbreHatiotls used i~1 this paper: DM, dermatomyositis; MCTD, mixed 
connective tissue disease; NEPHGE, non-equilibrium pH gradient dec- 
trophoresis; PM, polymyositis; RA, rhemnatoid arthritis. 
0-phenylenediamine as substrate using a microplate reader at 492 
nm. Standard curves were established using the polyclonal protea- 
some-specific antibody MP-3 and mouse anti-rabbit IgG peroxi- 
dase as secondary reagent. MP-3 was diluted in linear steps start- 
ing with 1:400. OD units of the dilution step 1:12,800 were 
considered to represent a value of 10,000 arbitrary units. There- 
fore, it was possible to make a direct correlation between the an- 
tibody reactivity of patients era of several assays. 112 sera from 
normal controls served to establish background reactivities. The 
mean value plus threefold SD were used as cutoff 
Monoclonal antiproteasome antibodies were used to support 
antiproteasome antibody specificity of patient sera. Multititer 
plates were coated with the antiproteasome antibody B65-BA5 
diluted 1:1,000 in carbonate buffer, pH 9.6. Purified proteasome 
was applied at a concentration of 10 ~tg/ml. Human sera were di- 
luted 1:100 and applied to each well for 2 h at room temperature. 
Further, goat anti-human IgG (Fc specific) peroxidase-labeled 
antibody (affinity-isolated antibodies, no cross-reactivity with 
mouse or rat IgG; Sigma Chemical Co., St. Louis, MO) were 
added 1:10,000. The antibodies bound were detected using 2-acino- 
bis-ethylbenzthiazolin-6-sulfate di mmonium as substrate and mea- 
sured at 405 nm. 
Statistical Analysis. Statistics were performed using the non- 
parametric U test (Mann and Whitney) and chi-square test with 
Yates correction to compare the qualitative and quantitative r ac- 
tivities to the proteasome among the patient's groups investi- 
gated. P values of <0.05 were considered to be statistically signif- 
icant. 
Results and Discussion 
Antiproteasome antibodies were detected by ELISA in 21 
o f  34 sera (62%) derived from PM (16/26) and DM (5/8) 
patients. Sera from patients with SLE reacted with protea- 
somes in 30 of  52 cases (58%) using ELISA. These frequen- 
cies of  antiproteasome antibodies were significantly higher 
than those found in patients with RA (P <0.001),  MCTD 
(P <0.025),  or in healthy controls (P <0.001) (Fig. 1). In 
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Figure 1, Autoinmmne response against proteasome was detected in 
patients with PM, DM, MCTD, and SLE. ELISA reactivities and median 
values of patients and healthy controls sera to purified 20S proteasome. 
Note that the two antiproteasome-positive sera of" healthy controls were 
not confirmed in further specific assays, The respective cut-offvalues are 
indicated (. . . .  ). The strongest autoinmmne r sponse was detected in 
sera of patients with PM, DM, and SEE. 
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Figure 2. Antiproteasome antibodies were confirmed in a stringent 
sandwich ELISA. Multititer plates were coated with the monoclonal 
mouse anti-human proteasome antibody B65-BA5, which served as the 
proteasome-specific reagent. Reactivities and median values of the main 
patient groups areshown. The respective cutoffvalues are indicated (- - - -). 
All sera of the healthy controls group were negative. The same sera ofpa- 
tients with PM, DM, and SLE revealed positive reaction in both ELISA 
assays. 
fact, sera of patients with PM/DM and SLE revealed a much 
stronger eactivity with 20S proteasome protein than sera 
from patients with RA (P <0.0005) and MCTD (P <0.025). 
Sera of  healthy controls gave a positive reaction in only 2 
of 112 cases (1.78%). 
To exclude the possibility that the above results were 
due to nonspecific binding of  antibodies and to unequivo- 
cally establish the antiproteasome specificity of  the auto- 
antibodies of  PM/DM and SLE patients, we performed 
sandwich ELISAs using the proteasome-specific mAb B65- 
BA5. In support of  the data shown in Fig. 1, 21 of  the 34 
sera tested from both PM and DM patients and 30 of  the 
52 sera from SLE were also positive in the more stringent 
sandwich ELISA (Fig. 2). Furthermore, the two positive 
MCTD sera were confirmed in that test. Importantly, the 
same patient sera were positive in both ELISA systems. In 
contrast, the two initially reactive sera from healthy con- 
trois as well as the one reactive RA serum were completely 
negative in the sandwich assay. 
There was no evidence for a statistical correlation be- 
tween the presence of antiproteasome antibodies and other 
routinely characterized antibody specificities. An exclusive 
presence of antiproteasome antibodies was only observed in 
sera from DM and PM patients. This contrasts with serum 
samples of  SLE, MCTD,  and RA patients, which predom- 
inantly reacted with other defined autoantigens uch as 
anti-native DNA antibodies (ds-DNA), anti-small nuclear 
ribonucleoprotein Smith (Sm), ant i -Ul -r ibonucleoprotein 
(U1-R.NP), or contained rheumatoid factor. Interestingly, 
of  the five sera which were positive for anti-histidyl tP, NA 
synthetase (Jo-1) antibodies only one serum from the myo-  
sitis group contained antiproteasome antibodies (Table 1). 
To see whether the antiproteasome autoantibodies ob- 
tained from patients with PM/DM and SLE react with sev- 
eral or a specific type ofproteasome subunits, the respective 
patient sera were probed on purified human erythrocyte 
20S proteasome in immunoblot  experiments. O f  the 21 
ELISA-positive myositis era a total of  16 (PM 13/16; DM 
3/5) were also positive in immunoblots. All five immuno-  
blot negative sera were of  tow antiproteasome titer as de- 
termined by ELISA. 14 of  the 16 antiproteasome autoanti- 
bodies of  PM/DM patients tested exclusively identified a 
single proteasomal subunit of  28 kD and thus revealed a re- 
markable subunit specificity (Fig. 3). The remaining two 
sera, besides exhibiting specificity for the 28-kD protein, 
also revealed weak reactivity with a proteasome subunit of  
23 kD. SLE patients recognized a single proteasomal sub- 
unit of  28 kD in 19 cases. Only three sera identified sub- 
units of  28 and of  23 kD simultaneously. Both positive 
MCTD sera recognized subunits of  28 kD, whereas the 
negative sera revealed no reactivity. It is important o note 
here that all ELISA-negative sera, including the sera from 
patients with PM/DM and SLE, were also proteasome 
negative in immunoblots (data not shown). 
Table 1. Distinct Autoantibody Profiles f the Different Disease Entities 
ANA dsDNA R.F 
IF IF APA* Jo-l* Scl-70" Sm* U1-R.NP* ELISA 
PM/DM (n = 34) 26 0 21 5 2 0 0 5 
SLE (n = 52) 50 45 30 0 0 8 12 12 
MCTD (n = 8) 8 0 2 0 1 0 8 2 
I<A (n = 20) 4 0 1 0 0 0 0 19 
Antinuclear antibodies (ANA) detected by indirect immunofluorescence in human larynx epithelioma cancer cell line (Hep-2 cells). The dilutuion 
sera was started at 1:80. Anti-native DNA antibodies (dsDNA) detected in specific Crithidia luciliae immunofluorescence test; dilution of sera was 
started at 1:2. Antiproteasome antibodies (APA), antihistidyl t <NA synthetase (Iol), anti-DNA topoisomerase I (Scl-70), anti-small nuclear ribonu- 
cleoprotein Smith (Sm), and anti-Ul-ribonucleoprotein (UI-RNP) specificities detected in ELISA and immunoblotting assays (dilution f the pa- 
tients sera 1:100). Rheumatoid factors (RF) of the IgM type measured using ELISA. Statistical analysis indicate that APA is a candidate asa new use- 
ful diagnostic marker ofautoimmune myositis. IF, immunofluorescence; IB, immunoblotting. 
*Antigens identified by immunoblotting and ELISA. 
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Figure 3. Patient sera detect a single proteasorual subunit in Western 
blot analysis. 208 proteasorues were isolated from human erythrocytes. 
Representative s ra react with a 28-kD subunit of the proteasorue. (A) 
Lane 1, 5 l, tg of purified proteasome, Cooruassie stained; lane 2, rabbit 
antiproteasome antibody MP-3 as a polyclonal Ab recognized several p o- 
teasomal subunits; lanes 3 and 4,sera of patients with PM; lane 5, serum 
of a patient with DM; lanes 6 and 7, sera of patients with SLE; lane 8, 
healthy control. All positive patients sera recognized a single subunit of 28 
kD. (B) Lane 1, rabbit antiproteasorue antibody MP3; lane 2, serum of a 
patient with PM; lanes 3 and4, sera of patients with SLE; lane 5, healthy 
control. 
The observation that the autoantibodies reacted predom- 
inantly with a single proteasome subunit  after SDS-PAGE 
led us to determine the identity of the subunit  after separa- 
tion of proteasome subunits by two-dimensional  electro- 
phoresis (Fig. 4). The high titer antiproteasome sera of 
PM/DM and SLE patients used in these experiments iden- 
tified a single protein which, as judged by its size, electro- 
phoretic mobil ity, and amino acid sequence, represents the 
proteasome o~-type subunit C9 (Fig. 4). 
In this communicat ion we have presented evidence that 
62% of  the sera from patients with PM/DM and 58% of  
SLE sera contain autoantibodies which react with the 208 
proteasome representing one of  the most abundant intrac- 
ellular proteins. Furthermore, we have demonstrated that 
Figure 4. Subunit C9 is the ruajor target ofpatients autoantibodies in 
two-dimensional electrophoresis f 208 proteasorue. Analyses were per- 
fornled with proteasorue of human erythrocytes (first dimension, 
NEPHGE; second dimension, SDS-PAGE). Arrow indicates (x-type ub  
unit C9. (A) Coomassie staining of a two-dimensional gel shows the puri- 
fied human proteasome. (B) Western blot analysis of two-dimensional 
electrophoresis detected by one representative serum of a patient with 
polyruyositis. Rabbit anti-hurnan IgG antibodies coupled with peroxidase 
served as the secondary reagents. Proteasorual co-type subunit C9 was rec- 
ognized by the patient serum. 
the proteasomal el-type subunit  C9 represents the predom- 
inant target o f  the autoantibodies occurring in myositis pa- 
tients. Skeletal muscle cells have been shown to represent 
APC by processing and presenting antigens to T cells via 
MHC class I and II pathways (23). In addition, skeletal 
muscle cells themselves can be targets of  auto immune at- 
tack in inf lammatory muscle diseases uch as polymyositis 
and dermatomyositis. Curiously, subunits of  the proteolytic 
enzyme complex responsible for the processing of MHC 
class I antigens are themselves targets of  autoantibodies. 
Previously reported myositis-specific autoantibodies recog- 
nize proteins of  RNP complexes involved in RNA pro- 
cessing, protein translation, or protein translocation (24). 
The association of  ant i - tRNA synthetase antibodies with 
myositis, arthritis, and interstitial lung disease led to the de- 
scription of  an entity designated as antisynthetase yndrome 
or anti-Jo-1 syndrome and represents the most common 
disease ofmyosit is ubgroups (13). 
Nevertheless, 80-85% ofmyosit is patients do not possess 
autoantibodies to the previously reported antigens (24, 25). 
Interestingly, only 5 of  34 sera from PM/DM patients 
tested were anti-Jo-1 positive and of  these only one also re- 
vealed reactivity with 208 proteasome. This demonstrates 
that there is an infrequent overlap in the induct ion of  au- 
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toantibodies to Jo-1 and proteasome in myositis patients. 
This indicates a discrimination between both groups of  pa- 
tients and supports the role of  antiproteasome C9 autoanti- 
body as a serological marker ofa myositis subset. 
It is of  special clinical interest hat the presence of  anti- 
proteasome antibodies was observed in active inflammatory 
muscle diseases in the PM/DM patients group. We ob- 
served that the antiproteasome-positive cases of  PM/DM 
revealed no manifestation of  interstitial ung disease. Fur- 
thermore, we found that in these positive myositis patients 
a high frequency of other organ involvement due to vascu- 
litis was seen. Remarkably, besides an active myositis he 
two antibody-positive MCTD patients revealed severe or- 
gan involvement. It is notable that all patients with SLE 
possessing antiproteasome antibodies also had severe organ 
manifestations like active nephritis and vasculitis of  the 
skin. Since these patients did not show any signs of  myosi- 
tis, it may be concluded that the antiproteasome antibodies 
not only do not indicate muscle involvement in autoim- 
mune diseases, but may also signify severe internal organ 
damage. 
In a previous study Arribas et al. (26) reported an anti- 
proteasome reactivity in 35% of SLE sera as judged by im- 
munoblotting, but were not able to detect antiproteasome 
antibodies in sera of  PM/DM patients. In that study it re- 
mained unclear, however, which of  the proteasome sub- 
units were recognized and whether they all were indeed 
subunits of  the enzyme complex. 
Here we demonstrate that antiproteasome antibodies 
represent one parameter for humoral autoimmune response 
in myositis. In addition to clinical and serological signs, like 
elevated levels of  creatinine kinase, antiproteasome anti- 
bodies are a candidate for a useful diagnostic marker. Initial 
data indicate a correlation with disease severity. Thus, clin- 
ical signs of  an active myositis and severe organ involve- 
ment appear to be related to the presence of antiprotea- 
some antibodies. However, the pathogenic importance of 
the antiproteasome antibodies and of the best-described au- 
toantibodies in systemic rheumatic diseases remains un- 
proven (27). One interesting aspect of  ongoing studies in 
our laboratories i the modulation of  the proteinase func- 
tion by antiproteasome antibodies. Therefore, epitopes that 
represent functional domains of  the C9 subunit could be 
antibody target sites. The C9 subunit possesses a nuclear lo- 
cation signal and is a component of  the outer oL-ring of  the 
proteasome which interacts with a number of regulators of  
proteasome activity. One of these is the 11S activator PA28 
which together with the 20S proteasome is directly in- 
volved in the MHC class I response of the cell. In recent 
reports it was shown that a large number of  autoantibodies 
are also present within the cell (28). If this turns out also to 
be true for the C9 autoantibody, a direct influence on the 
proteolytic function ofproteasomes appears possible. Nev- 
ertheless, more detailed studies will be necessary to deter- 
mine the relevance of an immune response to proteasomes 
with the predominant recognition of  the C9 subunit in pa- 
tients with autoimmune diseases. 
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